Botulinum neurotoxin serotype A inhibitors: Small-molecule mercaptoacetamide analogs

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 8, 2009, Pages 3072-3079

  Moe, Scott T ^a   Thompson, Andrew B ^a   Smith, Genessa M ^a   Fredenburg, Ross A ^b   Stein, Ross L ^b   Jacobson, Alan R ^a  

^a Absolute Science Inc   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BoNT A; Botulinum; Botulism; Mercaptoacetamides; Metalloprotease inhibitors

Indexed keywords

3 (2 CHLOROPHENYL) 1H PYRAZOL 5 AMINE; 3 (2 CHLOROPHENYL) 3 OXOPROPANENITRILE; 3 (3 (TRIFLUOROMETHYL)PHENYL) 1H PYRAZOL 5 AMINE; 3 (4 (TRIFLUOROMETHYL)PHENYL) 1H PYRAZOL 5 AMINE; 3 (4 CHLOROPHENYL) 1H PYRAZOL 5 AMINE; 3 (4 CHLOROPHENYL) 3 OXOPROPANENITRILE; 5 AMINO 3 PHENYLPYRAZOLE; BOTULINUM ANTISERUM; BOTULINUM TOXIN A; MERCAPTOACETAMIDE DERIVATIVE; METHYL 4 CHLOROBENZOATE; N (3 (2 CHLOROPHENYL) 1H PYRAZOL 5 YL) 2 MERCAPTOACETAMIDE; N (3 (2 TRICHLOROMETHYL)PHENYL) 1H PYRAZOL 5 YL) 2 MERCAPTOACETAMIDE; N (3 (3 CHLOROPHENYL) 1H PYRAZOL 5 YL) 2 MERCAPTOACETAMIDE; N (3 (4 BROMOPHENYL) 1H PYRAZOL 5 YL) 2 MERCAPTOACETAMIDE; N (3 (4 CHLOROPHENYL) 1H PYRAZOL 5 YL) 2 HYDROXYACETAMIDE; N (3 (4 CHLOROPHENYL) 1H PYRAZOL 5 YL) 2 MERCAPTOACETAMIDE; N (3 (4 CHLOROPHENYL) 1H PYRAZOL 5 YL) 3 MERCAPTOPROPANAMIDE; N (3 (4 CHLOROPHENYL) 1H PYRAZOL 5 YL) ACETAMIDE; N (3 (4 FLUOROPHENYL) 1H PYRAZOL 5 YL) 2 MERCAPTOACETAMIDE; N (3 (4 METHOXYPHENYL) 1H PYRAZOL 5 YL) 2 MERCAPTOACETAMIDE; N (3 (4 NITROPHENYL) 1H PYRAZOL 5 YL) 2 MERCAPTOACETAMIDE; N (3 (PHENYL) 1H PYRAZOL 5 YL) 2 MERCAPTOACETAMIDE; N (3 4 TOLYL 1H PYRAZOL 5 YL) 2 MERCAPTOACETAMIDE; N 3 (3 (TRIFLUOROMETHYL)PHENYL) 1H PYRAZOL 5 YL) 2 MERYL) 2 MERCAPTOACETAMIDE; N 3 (4 (TRIFLUOROMETHYL)PHENYL) 1H PYRAZOL 5 YL) 2 MERCAPTOACETAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG STRUCTURE; ENZYME INHIBITION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

BINDING SITES; BOTULINUM ANTITOXIN; BOTULINUM TOXIN TYPE A; DRUG DESIGN; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS; THIOACETAMIDE;

EID: 64049093179     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.03.013     Document Type: Article

References (36)

1. Schantz E.J., and Johnson E.A. Microbiol. Rev. 56 (1992) 80
2. Singh B.R. Nat. Struct. Biol. 7 (2000) 617
3. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., and Tonat K. J. Am. Med. Assoc. 285 (2001) 1059
4. Osborne S.L., Latham C.F., Wen P.J., Cavaignac S., Fanning J., Foran P.G., and Meunier F.A. J. Neurosci. Res. 85 (2007) 1149
5. For a review of botulinum neurotoxins see:. Willis B., Eubanks L.M., Dickerson T.J., and Janda K.D. Anew. Chem., Int. Ed. 47 (2008) 8360
6. Montecucco C. Trends Biochem. Sci. 11 (1986) 314
7. Schiavo G., Matteoli M., and Montecucco C. Physiol. Rev. 80 (2000) 717
8. Simpson L.L. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 167
9. Rosenbloom M., Leikin J.B., Vogel S.N., and Chaudry Z.A. Am. J. Therap. 9 (2002) 5
10. Schmidt J.J., Stafford R.G., and Bostian K.A. FEBS Lett. 435 (1998) 61
11. Schmidt J.J., and Stafford R.G. FEBS Lett. 532 (2002) 423
12. Oost T., Sukonpan C., Brewer M., Goodnough M., Tepp W., Johnson E.A., and Rich D.H. Biopolymers 71 (2003) 602
13. Brewer M., James C.A., and Rich D.H. Org. Lett. 6 (2004) 4779
14. Haug B.E., and Rich D.H. Org. Lett. 6 (2004) 4783
15. Sukonpan C., Oost T., Goodnough M., Tepp W., Johnson E.A., and Rich D.H. J. Pept. Res. 63 (2004) 181
16. Monteucco C., Papini E., and Schaivo G. FEBS Lett. 346 (1994) 92
17. Boldt G.E., Kennedy J.P., and Janda K.D. Org. Lett. 8 (2006) 1729
18. Capková K., Yoneda Y., Dickerson T.J., and Janda K.D. Bioorg. Med. Chem. Lett. 17 (2007) 6463
19. Natesh R., Schwager S.L., Evans H.R., Sturrock E.D., and Acharya K.R. Biochem. 43 (2004) 8718
20. Moe, S. T.; Jacobson, A. J. U.S. Patent Pending, 2007.
21. Moe, S.; Smith, G.; Thompson, A.; Fredenburg, R.; Stein, R.; Park, J.-B.; Tzipori, S.; Janda, K.; Silvaggi, N.; Allen, K.; Jacobson, A. 44th Annual Interagency Botulism Research Coordinating Committee (IBRCC), October 14-18, 2007; Asilomar, CA.
22. Moe, S. T.; Jacobson, A. J. U.S. Provisional Patent 61/1003,394, 2008.
23. Schmidt J.J., and Stafford R.G. Appl. Environ. Microbiol. 69 (2003) 297
24. Schmidt J.J., and Bostian K.A. J. Protein Chem. 14 (1995) 703
25. Schmidt J.J., and Bostian K.A. J. Protein Chem. 16 (1997) 19
26. Schmidt J.J., Stafford R.G., and Millard C.B. Anal. Biochem. 296 (2001) 130
27. Fredenburg, R. A.; Wilson, D.; Moe, S. T.; Jacobson, A. R.; Stein, R. L. 44th Annual Interagency Botulism Research Coordinating Committee (IBRCC); October 14-18, 2007, Asilomar, CA.
28. Lee, J. O.; Ramasamy, U.; Tzipori, S.; Moe, S. T.; Smith, G. M.; Jacobson, A. R.; Park, J. B. 44th Annual Interagency Botulism Research Coordinating Committee (IBRCC); October 14-18, 2007; Asilomar, CA.
29. Endo, Y.; Fujishima, H.; Murai, K.; Miyata, T.; Wakisaka, S.; Sasama, Y. U.S. Patent 5,739,083, April 14, 1998.
30. Allen, K. N. Boston University, private communication.
31. May P. The Chemistry of Synthetic Drugs. 2nd ed. (1918), Longmans, Green, London 23-25
32. 50 value of the hydroxamate (2) to that reported (Refs. 17 and 18).
33. Adler, M.; Apland, J. P.; Ternay, A.; Janda, K.; Deshpande, S. S. 44th Annual Interagency Botulism Research Coordinating Committee (IBRCC); October 14-18, 2007; Asilomar, CA.
34. Boldt G.E., Kennedy J.P., Hixon M.S., McAllister L.A., Barbieri J.T., Tzipori S., and Janda K.D. J. Comb. Chem. 8 (2006) 513
35. Baldwin M.R., Bradshaw M., Johnson E.A., and Barbieri J.T. Protein Expression Purif. 37 (2004) 187
36. Silvaggi N.R., Boldt G.E., Hixon M.S., Kennedy J.P., Tzipori S., Janda K.D., and Allen K.N. Chem. Biol. 14 (2007) 533